Event dossier

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Grouped from 2 articles across 2 sources.

2 reports2 sourcesMar 25, 2026, 2:38 PM
FilterCNBC
Clustered coverageCNBC, Financial Times
Coverage timeline2
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCMar 25, 2026, 2:38 PM

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Financial TimesMar 25, 2026, 12:59 AM

Merck nears $6bn biotech deal to boost cancer drug pipeline

Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.

El Psy Congroo Newswire